Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURF303 phase 2a/2b study of dabogratinib in low-grade upper tract urothelial carcinoma
MOH_2026-07-09_016928Phase 2Not yet recruiting
- Sponsor
- Tyra Biosciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabogratinib in upper tract urothelial carcinoma (UTUC) (4 arms), sponsored by Tyra Biosciences. Primary endpoint: Primary endpoint not reported. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
dabogratinib
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on MOH_2026-07-09_016928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-09_016928.